Rami Komrokji, MD

Articles

Unmet Needs and Future of Lower-Risk MDS

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Treatment Strategies and Sequencing in MDS

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Real-World Data for Luspatercept in Lower-Risk MDS

October 12th 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

October 5th 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

October 5th 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

September 28th 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

September 28th 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Clinical Insights into the COMMANDS Trial

September 21st 2023

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

September 21st 2023

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.

Final Thoughts on Recent Data Updates in MDS

August 17th 2023

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Key Trials in the Treatment of Higher-Risk MDS

August 10th 2023

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

August 10th 2023

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Oral HMAs in Lower-Risk MDS Treatment

August 3rd 2023

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

August 3rd 2023

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

July 28th 2023

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

July 28th 2023

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Treatment Approaches for Lower-Risk MDS With RAS Mutations

July 20th 2023

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

July 20th 2023

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Dr Komrokji on the Implications of the COMMANDS Trial in MDS

July 14th 2023

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

July 13th 2023

Panelists review the presented patient profile and shares how they would have approached treatment.